↓ Skip to main content

Dove Medical Press

Article Metrics

Tanezumab: a selective humanized mAb for chronic lower back pain

Overview of attention for article published in Therapeutics and Clinical Risk Management, February 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
39 Mendeley
Title
Tanezumab: a selective humanized mAb for chronic lower back pain
Published in
Therapeutics and Clinical Risk Management, February 2018
DOI 10.2147/tcrm.s144125
Pubmed ID
Authors

Michael Webb, Erik Helander, Bethany Menard, Richard Urman, Alan Kaye

Abstract

Chronic lower back pain is a significant disease that affects nearly 20% of the worldwide population. Along with hindering patients' quality of life, chronic lower back pain is considered to be the second most common cause of disability among Americans. Treating chronic lower back pain is often a challenge for providers, especially in light of our current opioid epidemic. With this epidemic and an increased aging population, there is an imminent need for development of new pharmacologic therapeutic options, which are not only effective but also pose minimal adverse effects to the patient. With these considerations, a novel therapeutic agent called tanezumab has been developed and studied. Tanezumab is a humanized monoclonal immunoglobulin G2 antibody that works by inhibiting the binding of NGF to its receptors. NGF is involved in the function of sensory neurons and fibers involved in nociceptive transduction. It is commonly seen in excess in inflammatory joint conditions and in chronic pain patients. Nociceptors are dependent on NGF for growth and ongoing function. The inhibition of NGF binding to its receptors is a mechanism by which pain pathways can be interrupted. In this article, a number of recent randomized controlled trials are examined relating to the efficacy and safety of tanezumab in the treatment of chronic lower back pain. Although tanezumab was shown to be an effective pain modulator in major trials, several adverse effects were seen among different doses of the medication, one of which led to a clinical hold placed by the US Food and Drug Administration. In summary, tanezumab is a promising agent that warrants further investigation into its analgesic properties and safety profile.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 13%
Student > Doctoral Student 5 13%
Other 4 10%
Student > Master 4 10%
Student > Bachelor 4 10%
Other 6 15%
Unknown 11 28%
Readers by discipline Count As %
Medicine and Dentistry 8 21%
Nursing and Health Professions 5 13%
Biochemistry, Genetics and Molecular Biology 4 10%
Agricultural and Biological Sciences 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Other 6 15%
Unknown 12 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2020.
All research outputs
#5,437,180
of 19,404,461 outputs
Outputs from Therapeutics and Clinical Risk Management
#264
of 1,164 outputs
Outputs of similar age
#98,946
of 288,915 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#7
of 25 outputs
Altmetric has tracked 19,404,461 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,164 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,915 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.